Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 2003. A report of the Australian Mycobacterium Reference Laboratory Network
DOI:
https://doi.org/10.33321/cdi.2004.28.51Keywords:
Mycobacterium tuberculosis, Mycobacterium bovis, laboratory diagnosis, tuberculosis, drug resistance, nucleic acid amplification testAbstract
The Australian Mycobacterium Reference Laboratory Network collected and analysed laboratory data on new cases of disease caused by Mycobacterium tuberculosis complex in the year 2003. A total of 784 cases were identified by bacteriology, representing an annual reporting rate of 3.9 cases of laboratory confirmed tuberculosis per 100,000 population. The most commonly encountered culture-positive specimens were sputum (n=351), lymph node (n=176) and from bronchoscopy (n=97). Smears containing acid fast bacilli were present in sputum (53.0%), bronchoscopy (32.0%) and lymph node (23.3%). Five children (female n=3, male n=2) under 10 years of age had bacteriologically confirmed tuberculosis. Eighty isolates of M. tuberculosis and one of Mycobacterium africanum (10.3%) were resistant to at least one of the standard anti-tuberculosis agents. Mono-resistance to isoniazid, ethambutol, rifampicin, and pyrazinamide was detected in 45, three, two, and one isolates respectively. Multidrug-resistance (MDRTB) defined as resistance to both isoniazid and rifampcin was observed in seven (0.9%) isolates. Of the seven MDRTB isolates, six were from the respiratory tract and four were from smear positive specimens. Of the 81 patients with drug resistant isolates, 78 (96.3%) were classified as having initial resistance; two had acquired resistance and no information was available for one isolate; five were Australian-born; and 76 (93.8%) had migrated from a total of 30 countries. Commun Dis Intell 2004;28:474–480.
Downloads
References
World Health Organization. Tuberculosis control in the WHO Western Pacific Region: 2004 report. ISBN 92 9061 090 5.
World Health Organization. Global tuberculosis control WHO report 2001. WHO/CDS/TB 2001.275. Geneva, World Health Organization.
Communicable Diseases Network Australia. National Strategic Plan for TB Control in Australia Beyond 2000. Commonwealth Department of Health and Ageing, Canberra, July 2002.
Australian Bureau of Statistics. Australian Demographic Statistics, June Quarter 2003.
World Health Organization. International Union Against TB and Lung Disease Global Project on Anti-tuberculosis drug resistance. 2001 WHO/CDS/TB/2001. Geneva, World Health Organization.
Dawson D, Anargyros P, Blacklock Z, Chew W, Dagnia H, Gow B, et al. Tuberculosis in Australia: an analysis of cases identified in reference laboratories in 1986–88. Pathology 1991;23:130–134.
Dawson D, Cheah DF, Chew F, Haverkort F, Lumb R, Sievers AS. Tuberculosis in Australia, 1989–1992. Bacteriologically confirmed cases and drug resistance. Med J Aust 1995;162:287–290.
Curran M, Dawson D, Cheah D. Laboratory surveillance of Mycobacterium tuberculosis isolates in Australia, 1992. Commun Dis Intell 1994;18:337–339.
Curran M, Dawson D. Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 1993. Commun Dis Intell 1995;19:343–345.
Dawson D. Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 1994 and 1995. Commun Dis Intell 1997;21:245–249.
Dawson D. Tuberculosis in Australia; bacteriologically confirmed cases and drug resistance, 1996. Commun Dis Intell 1998;22:183–188.
Dawson D. Tuberculosis in Australia; bacteriologically confirmed cases and drug resistance, 1997. Commun Dis Intell 1999;23:349–353.
Dawson D. Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 1998 and 1999. Commun Dis Intell 2001;25:261–265.
Lumb R, Bastian I, Dawson D, Gilpin C, Haverkort F, James G, Sievers A. Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 2000. Commun Dis Intell 2002;26:226–233.
Lumb R, Bastian I, Dawson D, Gilpin C, Haverkort F, James G, Sievers A. Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 2001. Commun Dis Intell 2003;27:173–180.
Lumb R, Bastian I, Chew W, Gilpin C, Haverkort F, Sievers A. Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 2002. Commun Dis Intell 2003;27:458–464.
Li J, Roche P, Spencer J, National TB Advisory Committee. Tuberculosis notifications in Australia, 2003. Commun Dis Intell 2004;28:464–474.
Lin M, Spencer J, Roche P, McKinnon M, National TB Advisory Committee. Tuberculosis notifications in Australia, 2000. Commun Dis Intell 2002;26:214–225.
Miller M, Lin M, Spencer J, National TB Advisory Committee. Tuberculois notifications in Australia, 2001. Commun Dis Intell 2002;26:525–536.
Samaan G, Roche P, Spencer J, National TB Advisory Committee. Tuberculosis notifications in Australia, 2002. Commun Dis Intell 2003;27:449–458.
Barnes PF. Rapid diagnostic tests for tuberculosis: progress but no gold standard. Am J Respir Care Med 1997; 155: 1497–1498.
Catanzaro A, Perry S, Clarridge JE, et al. The role of clinical suspicion in evaluating a new diagnostic test for active tuberculosis. JAMA 2000; 283: 639–645.
Piersimoni C, Scarparo C. Relevance of commercial amplification methods for direct detection of Mycobacterium tuberculosis complex in clinical samples. J Clin Microbiol 2003; 41: 5355–5365.
Centers for Disease Control and Prevention. Update: Nucleic acid amplification tests for tuberculosis. Morb Mortal Wkly Rep 2000; 49: 593–594.
Ausina V, Gamboa F, Gazapo E, et al. Evaluation of the semi-automated Abbott LCx Mycobacterium tuberculosis assay for direct detection of Mycobacterium tuberculosis in respiratory specimens. J Clin Microbiol 1996;35:1996–2002.
Moore DF, Curry JI. Detection and identification of Mycobacterium tuberculosis directly from clinical sputum sediments by ligase chain reaction. J Clin Microbiol 1998;36:1028–1031.
Downloads
Published
How to Cite
License
Copyright (c) 2004 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
